To include your compound in the COVID-19 Resource Center, submit it here.

Nektar reports Phase Ib data for NKTR-214/Opdivo combo in cancer

Nektar Therapeutics (NASDAQ:NKTR) reported interim response data from the dose-escalation Phase Ib portion of the Phase Ib/II PIVOT-02 trial evaluating NKTR-214 plus Opdivo nivolumab to treat advanced or metastatic solid tumors at the Society for Immunotherapy of

Read the full 372 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE